NasdaqGS:PTCTBiotechs
PTC Therapeutics (PTCT) Stock Drops As Profit Surge Meets Launch Concentration Risk
PTC Therapeutics stock just dropped almost 10% in a single session, yet the quarter it reported is the sort of print that usually forces investors to rerun their models rather than hit the sell button. The company delivered Q2 2026 revenue of about US$360.5m and swung to roughly US$1.01 in basic earnings per share, a sharp turn from the small loss in Q1. That combination of strong top line and a move back into the black, set against a sliding share price, is the expectation gap that matters...